ABSTRACT
BACKGROUNDS: An increasing incidence of Acute Myeloid Leukaemia (AML) has been reported in several Western countries. However, the epidemiology of AML in Asia is very limited. According to the National Comprehensive Cancer Network (NCCN) guideline of AML, a range of conventional therapy options is available to AML patients. Nevertheless, different treatment strategies may result in diverse healthcare utilization and costs. Understanding the treatment patterns, healthcare utilization and costs of AML would thus be essential for clinicians and policymakers to optimize the treatment strategies of AML. OBJECTIVES: The objective of this study was to investigate the incidence, treatment patterns, healthcare utilization and costs of AML in Taiwan using a nationwide population database. METHODS: We retrospectively identified AML patients diagnosed from 2006 to 2015 from the Taiwan Cancer Registry Database (TCRD) and estimated the epidemiology of AML in Taiwan. The TCRD was linked to National Health Insurance Research Database (NHIRD) to collect the treatment patterns and health care utilization. Patients diagnosed with AML from 2011 to 2015 were further identified to analyze treatment patterns, healthcare utilization and costs. RESULTS: The crude annual incidence of AML increased from 2.78 to 3.21 cases per 100,000 individuals from 2006 to 2015. However, the age-standardized rate (ASRs) of AML slightly declined from 2.47 to 2.41 cases per 100,000 individuals in the same period. Among 2,179 AML patients who received induction therapy (median age: 56 years), most of them (n = 1744; 80.04%) received standard-dose cytarabine (SDAC) regimen. The remaining 162 patients received high dose cytarabine (HDAC) and 273 patients received non-standard dose cytarabine (N-SDAC) regimen as the induction therapy. The median medical costs in our study for patients treated with chemotherapy alone was $42,271 for HDAC, $36,199 for SDAC and $36,250 for N-SDAC. For those who received hematopoietic stem cell transplantation (HSCT) after induction therapy, their median medical costs were $78,876 for HDAC, $78,593 for SDAC and $79,776 for N-SDAC. CONCLUSIONS: This study is the first population-based study conducted in Asia to provide updated and comprehensive information on epidemiology, treatment patterns and healthcare resource utilization and costs of AML.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Delivery of Health Care/economics , Hematopoietic Stem Cell Transplantation/economics , Leukemia, Myeloid, Acute , Registries , Adult , Aged , Allografts , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/economics , Costs and Cost Analysis , Female , Humans , Incidence , Leukemia, Myeloid, Acute/economics , Leukemia, Myeloid, Acute/epidemiology , Leukemia, Myeloid, Acute/therapy , Male , Middle Aged , Retrospective Studies , Taiwan/epidemiologyABSTRACT
Importance: Lifelong immunoglobulin replacement therapy (IRT) is standard-of-care treatment for congenital agammaglobulinemia but accrues high annual costs ($30â¯000-$90â¯000 per year) and decrements to quality of life over patients' life spans. Hematopoietic stem cell transplant (HSCT) offers an alternative 1-time therapy, but has high morbidity and mortality. Objective: To evaluate the cost utility of IRT vs matched sibling donor (MSD) and matched unrelated donor (MUD) HSCT to treat patients with agammaglobulinemia in the US. Design, Setting, and Participants: This economic evaluation used Markov analysis to model the base-case scenario of a patient aged 12 months with congenital agammaglobulinemia receiving lifelong IRT vs MSD or MUD HSCT. Costs, probabilities, and quality-of-life measures were derived from the literature. Microsimulations estimated premature deaths for each strategy in a virtual cohort. One-way sensitivity and probabilistic sensitivity analyses evaluated uncertainty around parameter estimates performed from a societal perspective over a 100-year time horizon. The threshold for cost-effective care was set at $100â¯000 per quality-adjusted life-year (QALY). This study was conducted from 2020 across a 100-year time horizon. Exposures: Immunoglobulin replacement therapy vs MSD or MUD HSCT for treatment of congenital agammaglobulinemia. Main Outcomes and Measures: The primary outcomes were incremental cost-effectiveness ratio (ICER) expressed in 2020 US dollars per QALY gained and premature deaths associated with each strategy. Results: In this economic evaluation of patients with congenital agammaglobulinemia, lifelong IRT cost more than HSCT ($1â¯512â¯946 compared with $563â¯776 [MSD] and $637â¯036 [MUD]) and generated similar QALYs (20.61 vs 17.25 [MSD] and 17.18 [MUD]). Choosing IRT over MSD or MUD HSCT yielded ICERs of $282â¯166 per QALY gained over MSD and $255â¯633 per QALY gained over MUD HSCT, exceeding the US willingness-to-pay threshold of $100â¯000/QALY. However, IRT prevented at least 2488 premature deaths per 10â¯000 microsimulations compared with HSCT. When annual IRT price was reduced from $60â¯145 to below $29â¯469, IRT became the cost-effective strategy. Findings remained robust in sensitivity and probabilistic sensitivity analyses. Conclusions and Relevance: In the US, IRT is more expensive than HSCT for agammaglobulinemia treatment. The findings of this study suggest that IRT prevents more premature deaths but does not substantially increase quality of life relative to HSCT. Reducing US IRT cost by 51% to a value similar to IRT prices in countries implementing value-based pricing may render it the more cost-effective strategy.
Subject(s)
Agammaglobulinemia/therapy , Cost-Benefit Analysis , Genetic Diseases, X-Linked/therapy , Hematopoietic Stem Cell Transplantation/economics , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/economics , Humans , Markov Chains , United StatesABSTRACT
Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard to morbidity associated with OM. Clinical information was gathered on 167 patients undergoing HSCT and divided according to the presence (n = 91) or absence (n = 76) of laser therapy and oral care. Cost analysis included daily hospital fees, parenteral nutrition (PN) and prescription of opioids. It was observed that the group without laser therapy (group II) showed a higher frequency of severe degrees of OM (relative risk = 16.8, 95% confidence interval -5.8 to 48.9, p < 0.001), with a significant association between this severity and the use of PN (p = 0.001), prescription of opioids (p < 0.001), pain in the oral cavity (p = 0.003) and fever > 37.8°C (p = 0.005). Hospitalization costs in this group were up to 30% higher. The introduction of oral care by a multidisciplinary staff including laser therapy helps reduce morbidity resulting from OM and, consequently, helps minimize hospitalization costs associated with HSCT, even considering therapy costs.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Low-Level Light Therapy , Opportunistic Infections/prevention & control , Oral Hygiene/methods , Stomatitis/therapy , Transplantation Conditioning/adverse effects , Adult , Aged , Allografts/economics , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/economics , Antifungal Agents/administration & dosage , Antifungal Agents/economics , Antifungal Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brazil , Case-Control Studies , Cost-Benefit Analysis , Dentists/economics , Drug Costs , Female , Hematopoietic Stem Cell Transplantation/economics , Hospital Costs , Hospitalization/economics , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/economics , Immunosuppressive Agents/therapeutic use , Low-Level Light Therapy/economics , Low-Level Light Therapy/methods , Male , Middle Aged , Myeloablative Agonists/economics , Myeloablative Agonists/therapeutic use , Narcotics/economics , Narcotics/therapeutic use , Opportunistic Infections/economics , Opportunistic Infections/etiology , Oral Hygiene/economics , Parenteral Nutrition/economics , Patient Care Team , Retrospective Studies , Self Care/economics , Stomatitis/economics , Stomatitis/etiology , Stomatitis/prevention & control , Transplantation Conditioning/economics , Transplantation, Autologous/economicsABSTRACT
In Brazil, the majority of the population does not have private health insurance and the government provides universal health care. Our 'Unique Healthcare System' pays for 95% of the 1500 hematopoietic stem cell transplants (HSCT) performed in the country every year. Hospitals are reimbursed a flat rate, ranging from US$ 13,000 for autologous to US$ 40,500 for unrelated donor transplants, excluding expenses with donor search and acquisition of the graft. The actual cost of the procedure is not captured routinely. Because unrelated donor recipients may have many clinical complications, most HSCT centers offer few or no beds to perform such transplants. The Pediatric Oncology Institute - GRAACC - is a non-profit organization that provides comprehensive care at no cost to the families, including unrelated donor HSCT. We are evaluating retrospectively the unrelated donor transplant costs to have data to present to the health authorities, looking for an appropriate funding formula for HSCT.
Subject(s)
Delivery of Health Care/economics , Hematopoietic Stem Cell Transplantation/economics , Organizations, Nonprofit/economics , Brazil , Child , Humans , Unrelated DonorsSubject(s)
Blood Transfusion, Autologous , Bone Marrow Transplantation , Cryopreservation , Hematopoietic Stem Cell Transplantation , Neoplasms/therapy , Specimen Handling , Blood Transfusion, Autologous/economics , Bone Marrow Transplantation/economics , Child , Cryopreservation/economics , Follow-Up Studies , Hematopoietic Stem Cell Transplantation/economics , Humans , National Health Programs/economics , Neoplasm Recurrence, Local/economics , Neoplasm Recurrence, Local/therapy , Specimen Handling/economics , Treatment OutcomeABSTRACT
BACKGROUND: Apheresis of granulocyte-colony-stimulating factor (filgrastim)-mobilized blood stem cells from normal donors is now being used in place of a marrow harvest in transplantation. How the adverse effects of and charges for this procedure compare with those of the standard marrow harvest is not known. STUDY DESIGN AND METHODS: Forty consecutive normal subjects who received filgrastim 96 micrograms/kg) subcutaneously twice daily for 4 to 6 days in preparation for apheresis were monitored prospectively by clinical and laboratory evaluation. RESULTS: Sixty-two percent of the subjects required oral analgesics. None discontinued filgrastim prematurely. Bone pain (82%), headache (70%), fatigue (20%), and nausea (10%) were reported. Filgrastim caused a mean eightfold increase in neutrophil counts, a mean twofold increase in lymphocyte counts, a mean twofold rise in alkaline phosphatase and lactate dehydrogenase levels, and minor changes in serum potassium, magnesium, and uric acid. Adverse events and laboratory effects resolved within 7 days after apheresis. No apheresis stem cell donor required transfusion or hospitalization, and only one required an additional clinic visit after completion of apheresis. By comparison, a retrospective analysis of 33 normal marrow donors demonstrated that all received transfusion(s), 3 were hospitalized, 3 required additional clinic visits after the marrow harvest. The median total charges related to the two procedures were comparable (p = 0.43), although the charges were significantly lower for donors requiring only one apheresis procedure (p = 0.002). CONCLUSION: Filgrastim mobilization and apheresis of blood stem cells constitute a safe, well-tolerated, and comparable or less expensive alternative to the traditional marrow harvest.